INGELHEIM, Germany--(BUSINESS WIRE)--Today, at the 25 th World Congress of Dermatology (WCD), Boehringer Ingelheim presented new late-breaking data from the EFFISAYIL™ 2 trial showing that spesolimab ...

LEO Pharma A/S, a global leader in medical dermatology, today announced new long-term results from EFFISAYIL® ON, an ongoing ...

Erosive pustular dermatosis (EPD) is a chronic inflammatory skin disorder predominantly affecting the scalp of older individuals, often in areas of pre-existing actinic damage and androgenetic ...

Localized pustular psoriasis is a term that refers to a limited area of small pus-filled blisters on your skin, typically on your hands or feet. It is distinct from generalized pustular psoriasis (GPP ...

Spevigo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 signaling. The Food and Drug Administration (FDA) has approved Spevigo ® (spesolimab-sbzo) for the treatment ...

The FDA has approved the monoclonal antibody spesolimab (Spevigo) as the first treatment for generalized pustular psoriasis (GPP), Boehringer Ingelheim announced. The approval stipulates use of the ...

INGELHEIM, Germany--(BUSINESS WIRE)--The U.S. Food and Drug Administration is the first regulatory authority to approve spesolimab as a treatment option for generalized pustular psoriasis (GPP) flares ...

Aaron Farberg, MD, and Mark G. Lebwohl, MD, discuss the relapsing nature of generalized pustular psoriasis and how the difficulty in diagnosing the disease affects outcomes for patients. Ryan ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Steven R. Feldman, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Spevigo for the treatment of generalized pustular psoriasis, Boehringer Ingelheim announced ...

Aaron Farberg, MD, and Mark G. Lebwohl, MD, discuss the common comorbidities seen in patients with generalized pustular psoriasis (GPP) and some potential future developments in the management of GPP.